|
Other drug use
Citations 81-90 of 124 total displayed.
|
Past content
(since Jul 1999):
|
- News
CMPA warns doctors of risks associated with prescribing marijuana
- Steven Wharry
Can. Med. Assoc. J. 2002; 166: 83.
[Full text]
[PDF]
- Letters
Personalized medications
- Véronique Koo
Can. Med. Assoc. J. 2001; 165: 1467-b-1468-b.
[Full text]
- Letters
The cost of maintaining adequate antidote supplies
- David Juurlink and Donald Redelmeier
Can. Med. Assoc. J. 2001; 165: 1467-a.
[Full text]
[PDF]
- Letters
Personalized medications
- Michelle Fischbach) and Jennifer Gold
Can. Med. Assoc. J. 2001; 165: 1468.
[Full text]
[PDF]
- Research
Prescription of methylphenidate to children and youth, 1990–1996
- Anton R. Miller, Christopher E. Lalonde, Kimberlyn M. McGrail, and Robert W. Armstrong
Can. Med. Assoc. J. 2001; 165: 1489-1494.
[Abstract]
[Full text]
[PDF]
- Commentary
Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder
- Benedetto Vitiello
Can. Med. Assoc. J. 2001; 165: 1505-1506.
[Full text]
[PDF]
- Commentary
Statistics and drug utilization: Are prescribing rates really that high?
- Steve Morgan
Can. Med. Assoc. J. 2001; 165: 1507-1508.
[Full text]
[PDF]
- News
Just the facts
- Michael OReilly
Can. Med. Assoc. J. 2001; 165: 1525-a.
[Full text]
[PDF]
- Research
Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs
- Paul V. Grootendorst, Lisa R. Dolovich, Bernie J. O'Brien, Anne M. Holbrook, and Adrian R. Levy
Can. Med. Assoc. J. 2001; 165: 1011-1019.
[Abstract]
[Full text]
[PDF]
[ [Online Tables] ]
- Commentary
Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario
- Joe T.R. Clarke, Dominick Amato, and Raisa B. Deber
Can. Med. Assoc. J. 2001; 165: 595-596.
[Full text]
[PDF]
[ [Online Appendix] ]
|
|
